| SECTOR | INDUSTRY |
| Health Care | Biotechnology |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Cynthia McLaughlin
Rosalio Madrigal
Cynthia McLaughlin
Jenna Brashear
Rosalio Madrigal
| Share Statistics | COAG | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,862.9 | $272.7 | 53% |
|
| Shares Out (Mil) | 30.1 | 54.1 | 37% |
|
| Institutional Ownership | 99.4% | 93.0% | 87% |
|
| Float (Mil) | 20.3 | 42.3 | 29% |
|
| Beta | na | 0.95 | na |
|
| Avg Daily Volume (000s) | 363 | 471 | 55% |
|
| Price Change (52-week) |
na | 56.7% | na |
|
| Growth | COAG | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.1% | na |
|
| Net Income (5yr) | na | (10.1%) | na |
|
| EPS (5yr) | na | 15.7% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.6%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 4 | 4 | 4 | |
| Current EPS | ($0.510) | ($3.100) | ($2.538) | |
| Month Ago EPS | ($0.487) | ($3.063) | ($2.513) | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | ($0.460) | ($3.035) | ($2.325) | |
| Year/Year Chg | (36.4%) | (95.4%) | (95.2%) | |
| Financials | COAG | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($83) | ($43) | 12% |
|
| EPS (TTM) | ($10.055) | ($1.600) | 4% |
|
| Operating Cash Flow (TTM) (Mil) | ($77) | ($31) | 7% |
|
| Net Cash Flow (TTM) (Mil) | $137 | $2 | 80% |
|
| Long-Term Debt (Q1) (Mil) | $1 | $4 | 15% |
|
| Enterprise Value (Q1) (Mil) | $1,957 | $185 | 49% |
|
| Valuation | COAG | Industry Median |
Percentile (All Stocks) |
|
| P/B | 4.10 | 2.68 | 74% |
|
| P/E | na | 19.6 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | COAG | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.6% | na |
|
| Net Margin | na | (73.5%) | na |
|
| ROA | (35.6%) | (47.9%) | 15% |
|
| ROE | (36.6%) | (55.0%) | 18% |
|
| Liabilities to Assets | 2.9% | 29.7% | 1% |
|
| F-Score | 1 | 3 | na |
|
Hemab Therapeutics Holdings, Inc. did not pass any screens on 9/10/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors
